Abstract: The present invention includes compounds useful as intermediates in the preparation of macrolactams, methods for preparing the intermediates, and methods for preparing macrolactams. One use of the methods and intermediates described herein is in the production of macrolactam compounds able to inhibit HCV NS3 protease activity.

Abstract: A liquid component concentration meter measures the concentration of a liquid in a liquid supply tube from outside the liquid supply tube. The concentration meter includes a liquid supply tube; a light transmission unit; a light emission unit for irradiating light to the light transmission unit; a light reception unit for receiving light passed through the light transmission unit; a support member that movably supports the light emission unit and the light reception unit such that a measurement position is moved along the light transmission unit; a measurement-position moving mechanism for moving the support member such that the measurement position is moved within a predetermined area in the light transmission unit; and a data processing unit for calculating the concentration of the liquid in the liquid supply tube based on intensities of light received by the light reception unit at different measurement positions.

Abstract: The concentration of a liquid in a liquid supply tube, which is supplied with the liquid, is stably measured from the outside of the liquid supply tube.

Abstract: Processes for the preparation of certain [3.1.0]hexane derivatives which are useful as mGluR agonists, and intermediates prepared during such processes.

Abstract: The present invention is directed to a process for preparing ?,? disubstituted ?-lactam derivatives of formula (I) that are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The compounds are useful in the treatment of certain disorders, including emesis, urinary incontinence, depression, and anxiety.

Abstract: This invention is related to a method for producing 3-{4-[3-(1-pyrrolidinyl)propoxy]phenyl}-5-trifluoromethyl-4(3H)-quinazolinone comprising a step for reacting 2-methyl-5-trifluoromethyl-4H-3,1-benzoxazin-4-one with 4-[3-(1-pyrrolidinyl)propoxy]aniline or an acid-addition salt thereof, or 4-(1-cyclobutyl-4-piperidinoy9oxyaniline or acid addition salt thereof in the presence of an acid catalyst.

Abstract: The invention is directed to a compound of the structural formula (22) (22) crystal form of structural formulae (21) and its free acid, pharmaceutical compositions comprising these compounds and methods of preparing and using these compounds.

Abstract: The present invention relates to synthetic processes useful in the preparation of fluorinated 4-azasteroid derivatives that modulate androgen receptors and have application in the treatment of conditions caused by androgen deficiency or androgen receptor hyperactivity, such as osteoporosis, periodontal disease, bone fracture, frailty, erectile dysfunction, loss of libido, androgen-dependent cancers and sarcopenia. The present invention also encompasses intermediates useful in the disclosed synthetic processes and the methods of their preparation.

Abstract: Processes for the preparation of certain [3.1.0]hexane derivatives which are useful as mGluR agonists, and intermediates prepared during such processes.

Abstract: The present invention relates to synthetic processes useful in the preparation of fluorinated 4-azasteroid derivatives that modulate androgen receptors and have application in the treatment of conditions caused by androgen deficiency or androgen receptor hyperactivity, such as osteoporosis, periodontal disease, bone fracture, frailty, erectile dysfunction, loss of libido, androgen-dependent cancers and sarcopenia. The present invention also encompasses intermediates useful in the disclosed synthetic processes and the methods of their preparation.

Abstract: Amine salts of 3-{2-oxo-3-[3-(5,6,7,8-tetrahydro[1,8]naphthyridin-2-yl)-propyl]imidazolidin-1-yl}-3-(6-methoxy-pyridin-3-yl)propionic acid are potent antagonists of the integrin ?v?3 receptor and are useful for the prevention and/or treatment of osteoporosis and vascular restenosis, as well as conditions associated with excessive angiogenesis, such as macular degeneration, diabetic retinopathy, atherosclerosis, inflammatory arthritis, cancer, and metastatic tumor growth. The invention also relates to a process for the preparation of the novel salts as well as pharmaceutical compositions containing the salts and methods of using the salts.

Abstract: Amine salts of 3-{2-oxo-3-[3-(5,6,7,8-tetrahydro[1,8]naphthyridin-2-yl)-propyl]imidazolidin-1-yl}-3-(6-methoxy-pyridin-3-yl)propionic acid are potent antagonists of the integrin &agr;v&bgr;3 receptor and are useful for the prevention and/or treatment of osteoporosis and vascular restenosis, as well as conditions associated with excessive angiogenesis, such as macular degeneration, diabetic retinopathy, atherosclerosis, inflammatory arthritis, cancer, and metastatic tumor growth. The invention also relates to a process for the preparation of the novel salts as well as pharmaceutical compositions containing the salts and methods of using the salts.

Abstract: A novel process is provided for the preparation of optionally protected 2,5-di-(3′-aminopropyl)-pyridines which are useful in the synthesis of &agr;v integrin receptor antagonists. Also provided are useful intermediates obtained from the process.

Abstract: The invention discloses a novel process for the preparation of enantiomerically enriched mixtures of compounds of structural formula I which are useful intermediates in the synthesis of &agr;v&bgr;3 integrin receptor antagonists

Abstract: A photometer comprises a projecting mechanism irradiating a physical mass with infrared light within a wavelength region of 1.1 to 2.0 &mgr;m, a photoreceiving mechanism receiving output light from the physical mass and a spectroscope separating the light applied to the physical mass or the output light from the physical mass into its spectral components, for measuring absorbance by the physical mass at a specific wavelength. A compression mechanism can compress a measured region of the physical mass or a peripheral portion thereof, and difference absorbance calculator obtains difference absorbance from first absorbance obtained by the photometer under a state compressed by the compression mechanism with a first pressure and second absorbance obtained by the photometer under a state compressed with a second pressure lower than the first pressure or a non-compressed state.

Abstract: The invention discloses a novel process for the preparation of enantiomerically enriched mixtures of compounds of structural formula I which are useful intermediates in the synthesis of &agr;v&bgr;3 integrin receptor antagonists.

Abstract: Processes are disclosed for preparing 3-hydroxymethylcyclopentanone compounds, which are useful as intermediates in the preparation of HIV chemokine CCR-5 receptor antagonists. A process is described in which the compounds are prepared by opening the cyclopropyl ring of a (1-alkoxycarbonyl-2-oxo)-trans-bicyclo[3.1.0]hexane compound by addition of a nucleophile to the cyclopropyl ring, and then decarboxylating the resulting 2-alkoxycarbonyl-3-(Nu-methyl)-cyclopentanone (Nu=the added nucleophilic group) via base solvolysis. Also described is a process for preparing the bicyclo[3.1.0]hexane precursors by the catalyzed cyclopropanation of a suitable alpha-diazo-beta-ketoester. The preparation of the alpha-diazo-beta-ketoesters and precursors thereto are also disclosed.

Abstract: A novel process is provided for the preparation of optionally protected 2,5-di-(3′-aminopropyl)-pyridines which are useful in the synthesis of &agr;v integrin receptor antagonists. Also provided are useful intermediates obtained from the process.

Abstract: A process of synthesizing a carbapenem compound of formula (6) is disclosed, wherein R represents H or methyl, P and P* independently represent H or protecting groups and each R1 is independently selected from: H, halo, OH, OP wherein P is a protecting group, C1-6 alkyl or C1-6 alkyl substituted with 1-3 of halo, OH, OP, NH2, NHC1-4 alkyl or N(C1-4 alkyl)2, comprising reacting a carbapenem of formula (4′) with a compound of formula (7), wherein R, R1, P and P* are as previously defined and R2 represents acetate, C(O)OR′ or P(O)(OR″)2, wherein R′ and R″ independently represent Clot alkyl, benzyl or aryl, in the presence of a catalyst to produce a compound of formula (6).

Abstract: A second optical component is an optical fiber bundle charged in a clearance between an inner cylinder and an outer cylindrical outer peripheral part in the form of a ring. These elements are integrated with each other, and forward-end-surfaces thereof are on concentric circles. A ring of the forward-end-surface of the outer peripheral part is larger in width than the ring of the forward-end-surface of the second optical component. A first optical component charged with an optical fiber bundle is slidably inserted into and engaged in the cylinder inside the second optical component, so that the forward-end-surface of the first optical component can project or retract from the forward-end-surface of the outer peripheral part.